During this segment, Peter Salgo, MD; Ira M. Klein, MD, MBA, FACP; Michael Kolodziej, MD; and Bryan Loy, MD, discuss appropriate settings for conducting clinical studies that can help evaluate quality metrics and improve patient care, and describe challenges related to the use of patient-reported outcomes in medical oncology.
Dr Loy explains that both academic and nonacademic institutions can play an important role in research and provide valuable information regarding outcomes and variations. Although the site of care often impacts the ability to deploy metrics, receive data on metrics, and then discuss the results, having consensus among all stakeholders regarding the metrics to be evaluated is more important to improving quality than the site of care, adds Dr Klein.
Furthermore, Dr Klein comments that the usefulness of patient-reported outcomes has yet to be determined in medical oncology and suggests that the information collected from these surveys should be used with caution.
Dr Kolodziej notes that patient-reported outcomes information is currently reported in aggregate, and remarks that a methodological approach that allows individual-level reporting needs to be established to link the patient-reported outcomes information with other clinical factors including clinical outcomes.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More